J&J Talks Up Wellness As Economy, Generics Shadow ’09
Executive Summary
Johnson & Johnson CEO William Weldon emphasized the company's emerging wellness and prevention strategy during a year-end sales and earnings presentation Jan. 20, in which the macroeconomic climate, loss of Risperdal and declining sales of Procrit weighed on the pharmaceutical segment's top line